Publications

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

11 July 2023

This report contributes to the understanding of people’s proximity to dementia (e.g., people with dementia and their carers forecast) and so the potential future number of people who will be impacted by dementia, and the economic benefits arising from dementia research in the UK.

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

19 May 2023

In this report, we propose a novel payment model that will incentivise broader value demonstration for diagnostics for antibiotics that could inform longer-term financing and reimbursement arrangements and guide prescribing behaviours.

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

15 May 2023

In this report, we discuss best practices for RWE generation and the steps needed to enhance the assessment and use of quality RWE in reimbursement decisions.

Delivering the Triple Win: A Value-Based Approach to Pricing

Delivering the Triple Win: A Value-Based Approach to Pricing

20 April 2023

In this report, we investigate the theory and practice of value-based pricing in the pharmaceuticals industry, and provide recommendations for how implementation of value-based pricing can be enhanced to deliver the triple win of patient access; healthcare system sustainability; and innovation.

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism

30 March 2023

In this report, we describe the design of a globally aligned, value-based, fully-delinked pull incentive, where payers provide manufacturers with a pre-specified subscription fee based on the value of the antibiotic, regardless of the volume used.

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

2 June 2023

In this report, we explore the status of access and uptake for NGS testing for lung cancer in Europe, develop the health economic case for NGS testing, and identify barriers and opportunities for widespread access.

Navigating the Landscape of Digital Health - United Kingdom

Navigating the Landscape of Digital Health – United Kingdom

16 December 2022

Digital Health Technologies are a major trend in health care, and successfully adding them to the wider portfolio of health technologies requires coordinated involvement from various stakeholders.

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

30 November 2022

An increasingly common strategy for treating many cancers is to utilise several medicines with distinct but complementary mechanisms of action in combination or in close sequence…

Cracks through the ice on a melting glacier in Alaska

2021 OHE Annual Report to the Charity Commission

1 December 2022

OHE obtained its charitable status in 2016, an essential achievement towards OHE’s development as a health economics research organisation. The report of 2021 demonstrates some of…